Ligand Pharmaceuticals 

$314.88
46
-$4.55-1.42% Wednesday 19:59
+$10.12+3.21%Wednesday 23:57盤後

統計

當日最高
315.87
當日最低
315
52週高點
326.63
52週低點
116.44
成交量
7,671
平均成交量
-
市值
6.31B
本益比
41.78
股息殖利率
-
股息
-

即將到來

股息

0%股息殖利率
Jul 10
$0.46
Apr 7
$15.00
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

11Aug預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
下一步
1.19
1.82
2.46
3.09
預期EPS
1.95125
實際EPS
不適用

財務

46.42%利潤率
有盈利
2020
2021
2022
2023
2024
2025
268.09M營收
124.45M淨利

分析師評級

281.00平均目標價
最高預估為 332.00。
來自過去6個月內的 6 則評分。這不是投資建議。
買入
100%
持有
0%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 LGND 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Show more...
執行長
Mr. Todd C. Davis Ph.D.
員工
68
國家
美國
ISIN
US53220K5048

上市

0 Comments

分享你的想法

FAQ

Ligand Pharmaceuticals 今天的股價是多少?
LGND 目前價格為 $314.88 USD,過去 24 小時下跌了 -1.42%。在圖表上更密切關注 Ligand Pharmaceuticals 股票的表現。
Ligand Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 XNAS 交易所,Ligand Pharmaceuticals 的股票以代號 LGND 進行交易。
Ligand Pharmaceuticals 的股價在上漲嗎?
LGND 股票較上週下跌 -1.46%,本月上漲 +29.43%,過去一年 Ligand Pharmaceuticals 上漲 +157.25%。
Ligand Pharmaceuticals 的市值是多少?
今天 Ligand Pharmaceuticals 的市值為 6.31B
Ligand Pharmaceuticals 下一次財報日期是什麼時候?
Ligand Pharmaceuticals 將於 August 11, 2026 公布下一次財報。
Ligand Pharmaceuticals 上一季度的財報如何?
LGND 上一季度的財報為每股 1.63 USD,預估為 1.82 USD,帶來 -10.23% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Ligand Pharmaceuticals 去年的營收是多少?
Ligand Pharmaceuticals 去年的營收為 268.09MUSD。
Ligand Pharmaceuticals 去年的淨利是多少?
LGND 去年的淨收益為 124.45MUSD。
Ligand Pharmaceuticals 會發放股息嗎?
是的,LGND 的股息每 zh-tw 發放一次。每股最新股息為 0.46 USD。截至今日,股息殖利率(FWD)% 為 0%。
Ligand Pharmaceuticals 有多少名員工?
截至 July 09, 2026,公司共有 68 名員工。
Ligand Pharmaceuticals 位於哪個產業?
Ligand Pharmaceuticals從事於Health & Wellness產業。
Ligand Pharmaceuticals 何時完成拆股?
Ligand Pharmaceuticals 上次拆股發生於 November 19, 2010,比例為 1:6。
Ligand Pharmaceuticals 的總部在哪裡?
Ligand Pharmaceuticals 的總部位於 美國 的 Jupiter。